We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

37 hedge funds and large institutions have $92.7M invested in SAB Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

42% more funds holding

Funds holding: 26 → 37 (+11)

41% more capital invested

Capital invested by funds: $65.9M → $92.7M (+$26.9M)

1.82% more ownership

Funds ownership: 4.53% → 6.36% (+1.8%)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

Holders
37
Holders Change
+11
Holders Change %
+42.31%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
6
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$5.28M
2
KC
Kepos Capital
New York
+$5.24M
3
KIM
Karpus Investment Management
New York
+$4.38M
4
BFM
Boothbay Fund Management
New York
+$3.97M
5
CH
CVI Holdings
Delaware
+$3.47M

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$5.09M
2
HSBC Holdings
HSBC Holdings
United Kingdom
-$979K
3
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$496K
4
MSU
Mizuho Securities USA
New York
-$205K
5
WAM
Wolverine Asset Management
Illinois
-$182K
Name Holding Trade Value Shares
Change 		Change in
Stake
CM
26
Crestline Management
Texas
$505K +$502K +5,061 New
DWM
27
Dakota Wealth Management
Florida
$504K +$502K +5,058 New
Citadel Advisors
28
Citadel Advisors
Florida
$382K -$77.1K -777 -17%
Millennium Management
29
Millennium Management
New York
$365K +$364K +3,666 New
Jane Street
30
Jane Street
New York
$359K +$173K +1,748 +94%
JP Morgan Chase
31
JP Morgan Chase
New York
$269K – – –
EAM
32
Exos Asset Management
New York
$249K -$397 -4 -0.2%
UBS Group
33
UBS Group
Switzerland
$15K +$6.05K +61 +70%
TRCT
34
Tower Research Capital (TRC)
New York
$1K +$893 +9 New
Walleye Capital
35
Walleye Capital
New York
$776 +$773K +7,793 New
MF
36
Magnetar Financial
Illinois
$140 +$139K +1,405 New
MP
37
Mangrove Partners
Connecticut
– -$5.09M -51,838 Closed
WAM
38
Weiss Asset Management
Massachusetts
– -$100K -1,019 Closed
HighTower Advisors
39
HighTower Advisors
Illinois
– -$98K -1,000 Closed
Morgan Stanley
40
Morgan Stanley
New York
– -$1K -13 Closed
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
– +$99 +1 New
1
2

SABS Hedge Fund Activity: Q2 2021 in Review

37 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2021, worth a combined $92.7M — up 41% from $65.9M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new SABS positions and 4 closed out — a net gain of 11 holders — while 6 added to existing stakes and 7 trimmed.

The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $5.28M. The largest seller was Mangrove Partners, exiting entirely with an estimated $5.09M sold.

  • 37 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2021, up from 26 in Q1 2021.
  • Funds reported $92.7M of SAB Biotherapeutics stock for Q2 2021, up 41% quarter-over-quarter.
  • 15 funds opened new SAB Biotherapeutics positions in Q2 2021 and 4 closed out, a net change of +11 holders.
  • The largest SAB Biotherapeutics buyer in Q2 2021 was Glazer Capital LLC, an estimated $5.28M added.
  • The largest SAB Biotherapeutics seller in Q2 2021 was Mangrove Partners, an estimated $5.09M sold.

Based on aggregated 13F filings for Q2 2021.